Professor Arkenau is a world-class expert and global authority in the clinical and translational development of cancer treatments. His experience has been built across a career spanning over 300 oncology trials at all stages of development.

Prior to joining Ellipses, Professor Arkenau was the Executive Medical Director of Sarah Cannon Research Institute UK, where for the last 12 years he led a broad portfolio of early and translational oncology assets and successfully supported multiple pharma and biotech companies in their strategic development. He was previously a senior clinical fellow at the Royal Marsden hospital, and team leader for early drug development at the Prince of Wales Clinical School at the University of New South Wales, Australia.

He currently holds positions as Honorary Professor at University College London, Cancer Institute and Consultant Oncologist at University College London Hospital.